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A B S T R A C T
Three novel glass compositions, identified as NCL2 (SiO2-based), NCL4 (B2O3-based) and NCL7 (SiO2-based),
along with apatite-wollastonite (AW) were processed to form sintered dense pellets, and subsequently evaluated
for their in vitro bioactive potential, resulting physico-chemical properties and degradation rate.
Microstructural analysis showed the carbonated hydroxyapatite (HCA) precipitate morphology following SBF
testing to be composition-dependent. AW and the NCL7 formulation exhibited greater HCA precursor
formation than the NCL2 and NCL4-derived pellets. Moreover, the NCL4 borate-based samples showed the
highest biodegradation rate; with silicate-derived structures displaying the lowest weight loss after SBF
immersion. The results of this study suggested that glass composition has significant influence on apatite-
forming ability and also degradation rate, indicating the possibility to customise the properties of this class of
materials towards the bone repair and regeneration process.
1. Introduction
Since the first proposed glass (currently known as Bioglass®)
developed by Hench in 1969, and intended for bone tissue applications
[1,2], bioactive glasses become a class of biomaterials which are still
widely investigated [3].
Among inorganic biomaterials, Bioglass® has received great atten-
tion for its ability to form a strong bond with soft as well as hard host
tissue, resulting in what has been recognised as bioactive behaviour [4].
The concept of bioactivity was introduced by Hench at the beginning of
70's, when he described the bonding of 45S5 bioglass to bone as a
process based on the formation of a carbonated hydroxyapatite (HCA)
layer on the surface of the material in contact with the host tissue [2].
The development of this glass revolutionised the definition of bioma-
terial, moving the perspective from inert to a material that, interacting
with the human body, is capable to elicit a specific biological response
[5].
Around a decade later in Japan Kokubo et al. were the first to
synthetize a new glass-ceramic material currently known as apatite-
wollastonite [6]. This bioceramic demonstrated excellent mechanical
properties and an exceptional ability to form a strong chemical bond
with bone tissue [7,8]. In 1990, Kokubo described the capacity of a
material to develop an HA-like layer on its surface, when immersed in a
simulated body fluid (SBF) solution, as indicative of its bioactivity [9].
The SBF proposed by Kokubo mimics human blood plasma in terms of
pH and ionic concentration and it is the most applied preliminary in
vitro test to assess the bioactive potential of biomedical materials [10].
Many new bioactive formulations in the silicate, phosphate and
borate-based system and with variable types of modifiers have been
designed [11–13]. However, it has been found that small variations in
the glass main formulation greatly affect material properties such as
degradation rate and bioactive potential [14–17].
For the first time, highly complex bioceramic formulations (belong-
ing to the silicate and borate-based glass family), containing different
doping agents (i.e. MgO, MnO2, Al2O3, CaF2, Fe2O3, ZnO, CuO, Cr2O3)
and in diverse weight percentages, were produced via a melting-
quenching method [19] and demonstrated good potential as biomater-
ials for bone tissue applications. Following the desirable requirement to
develop materials with sufficient bioactivity and controllable degrada-
tion behaviour, the motivation of the present work was to evaluate the
effect of these novel bioceramic compositions on apatite-forming ability
and degradation rate upon immersion in simulated body fluid (SBF)
solution. The novel materials, processed in form of dense sintered
pellets (see Fig. 1), were investigated in terms of crystallinity by X-ray
diffraction (XRD) and morphological structure through scanning
electron microscopy (SEM) before and after 28 days immersion in
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SBF. Furthermore, the chemical composition of the precipitates was
assessed by using x-ray photoelectron spectroscopy (XPS) and energy
dispersive spectroscopy (EDX). In addition, measurements of the pH
variations, degradation behaviour and ion leaching potential were
conducted.
2. Materials and methods
2.1. Preparation of bioceramic samples and characterisation
Three novel bioceramic formulations were investigated in this
study, together with AW, selected as a well characterised comparator
material (see Table 1). All the glasses were produced and supplied by
Glass Technology Service (GTS) Ltd (Sheffield, UK). The glass frits as
received were processed to compact pellets, following the same
procedure described in [18].
Briefly, bioceramic pellets were prepared by cold pressing raw glass
powders in a cylindrical stainless steel mould (diameter 10 mm) using
an automatic hydraulic press (Specac-Atlas™ 8T, Specac Ltd., UK).
Subsequently, the pressed pellets, also called green bodies, were treated
through a sintering process to consolidate their structure. Hence, they
were placed in a furnace (Carbolite 1200 CWF, Carbolite GmbH,
Germany) and sintered in accordance to data derived from hot stage
microscopy analysis [18], as shown in Table 2. Subsequently, XRD
analysis was performed on both sintered and un-sintered samples by
using a PANalytical X′Pert Pro MPD, powered by a Philips PW3040/60
X-ray generator fitted with an X′Celerator detector. Diffraction data
was acquired by exposing powder samples to Cu-Kα X-ray radiation,
which was supplied with 40 kV and a current of 40 mA. The data were
collected over a 2θ range between 5° and 80° (2θ), with a step size
equal to 0.0334°, a counting time per step of 200 s using the scanning
X′Celerator detector. Phase identification was carried out by means of
the PANalytical X′Pert HighScore Plus© software, in conjunction with
the ICDD Powder Diffraction File 2 Database (2004), ICDD Powder
Diffraction File 4 - Minerals (2014) and the Crystallography Open
Database (February 2013; www.crystallography.net).
2.2. In vitro bioactivity test in simulated body fluid
In order to assess the bioactive potential of the novel materials,
sintered pellets were soaked for 1, 3, 7, 14 and 28 days in SBF, which
was prepared following Kokubo's protocol [10].
Each sample was immersed in 10 ml of acellular SBF then
incubated at 37 °C. During the incubation time, the SBF solution was
replaced every two days to avoid ionic depletion in the SBF due to the
precipitation of inorganic salts on the samples’ surface.
At the end of each time interval, the samples were removed from
SBF, then gently rinsed with deionised water (Veolia Water
Technologies, UK) and dried at room temperature before starting
further characterisation.
2.3. Sample characterisation
2.3.1. Morphological and compositional analysis
The structural characteristics and chemical composition of the
upper surface of the samples were investigated by SEM/EDS (Philips
XL30 ESEM FEG, which is fitted with a Rontec Quantax system for the
EDS analysis). Before the imaging acquisition, the specimens were
sputtered with a thin layer of gold (approximately 10 nm, sputter time
40 s at 40 mA), and afterward analysed. All the images were taken at an
operation voltage of 20 kV, and working distance between 5 and
10 mm.
Additionally, to quantitatively evaluate the composition of the
precipitates, XPS analysis was performed using Theta Probe (Thermo
Scientific, East Grinstead, UK), with a micro-focused AlKa X-ray source
(1486.6 eV), operated with a 400 µm spot size (100 W power). Survey
spectra were collected at a pass energy of 200 eV, with the spectrometer
operated in standard (not angle-resolved) lens mode. The results were
expressed as the average of three points of each sample surface.
Fig. 1. Preparation and characterisation of novel sintered bioceramic pellets.
Table 1
Composition of the novel glass formulations.
CODE GLASS COMPOSITION (wt%)
NCL2 36.90SiO2 – 9.70P2O5 – 1.90B2O3 – 3.39Na2O – 11.48CaO – 3.85K2O
– 4.41MgO – 2.38MnO2 – 6.97Al2O3 – 2.13CaF2 – 10.92Fe2O3 –
0.41Li2O – 1.97MoO3 – 1.52SeO2 – 2.07Cr2O3
NCL4 16.28SiO2 – 9.63P2O5 – 37.77B2O3 – 4.21Na2O – 3.80CaO – 6.38K2O
– 2.73MgO – 5.52ZnO – 7.03SrO – 2.12CaF2 – 1.08CuO – 1.95MoO3
– 1.51SeO2
NCL7 39.96SiO2 – 9.46P2O5 – 12.39Na2O – 11.19CaO – 2.50K2O – 1.61MgO
– 15.44AgO – 2.13TiO2 – 4.26Fe2O3 – 1.06CuO
AW 4.6 MgO – 44.7 – CaO – 34 SiO2 – 16.2 P2O5 – 0.5 CaF2
Table 2
Heat treatments for dense pellets.
CODE SINTERING TREATMENT
NCL2 10°/min up to 700 °C, hold for 1 h
NCL4 10°/min up to 625 °C, hold for 1 h
NCL7 10°/min up to 625 °C, hold for 1 h
AW 10°/min up to 850 °C, hold for 1 h
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2.3.2. Weight loss, pH variation, and ionic leaching potential
The pH of the solutions was measured after each time point using a
pH meter (Mettler Toledo Ltd., UK), which was calibrated with
standard solutions (at pH 4 and 7) every time before use. Moreover,
the sample solubility was quantitatively assessed by measuring the
weight loss of the immersed pellets after 1, 3, 7, 14 and 28 days of
soaking, using an analytical balance (Kern ABT220-5DM), according to
the following formula:
Weight loss
M M
M
(%) =
−
× 100bi af
bi
where Mbi is the mass of the sample before the immersion and Maf is the
mass of the sample after the immersion. All the results were expressed
as average ± standard deviation (SD). Furthermore, in order to
evaluate the ionic release potential of each composition, the ion
concentration was measured using an inductively coupled plasma
optical emission spectrometer Specto-Ciros-Vision (Sheffield
University, UK), which allows simultaneous multi-element analysis
following the calibration of the instrument by introduction of standards
of known concentrations of the elements of interest.
3. Results and discussion
3.1. Sintering and crystal structure evolution
Sintered bioceramic pellets were successfully fabricated following
the heating treatment reported in Table 2, and based on the results
previously derived from HSM analysis [19]. Sintering temperatures,
which usually range from 30% to 90% of the melting temperature [20],
have been found to greatly depend on the material compositions [19]
and HSM revealed a powerful technique to identify the optimal
sintering intervals of the novel bioceramics. By comparing the XRD
patterns of the glass powders with those of the sintered bioceramic
pellets (see Fig. 2) we can observe that:
• The post sintering XRD pattern for NCL2 silicate-based glass
revealed the presence of a crystalline phase identified as diopside
(ICDD ref. code 01-073-6374). Diopside is a Mg-containing com-
pound, which has already been investigated as a biomaterial for
bone repair in powder and dense bulk ceramic forms [21].
Furthermore, diopside-derived scaffolds were found to possess good
and stable mechanical properties upon immersion in physiological
solution due to their low degradation rate [22].
• The XRD analysis confirmed the amorphous nature of NCL4
formulation even after sintering.
• The thermal process did not affect the crystallinity of NCL7 glass-
ceramic, which still showed a crystalline phase corresponding to
pure silver (ICDD ref. code 04-003-1425).
• The XRD patterns of AW samples revealed the same crystalline
phases (hydroxylapatite (ICDD ref. code 01-073-1731) complemen-
ted with β-wollastonite (ICDD ref. code 01-071-0880)) before and
after the sintering process, confirming the glass-ceramic nature of
this formulation [23].
3.2. Morphological analysis
The bioactivity of the sintered pellets before and after 7 and 28 days
in immersion in SBF solution was firstly evaluated through SEM and
EDX analysis, whose outcomes are reported in Figs. 3 and 4.
Of particular interest is the difference in behaviour of the two
silicate based formulations. No apatite nucleation was detected for
NCL2-based pellets (see Fig. 3(a)–(c)), which after 28 days in immer-
sion developed a homogeneous rough layer onto the sample surface
(Fig. 3(c)). Globular shaped agglomerates developed on NCL7 speci-
mens (Fig. 4(a)–(c)), with a consequent increase in the Ca/P ratio from
1.1 at day 7 to 1.4 at day 28 (Fig. 4(a)–(c)). These precipitates might be
considered HCA precursors (octacalcium phosphate), and therefore
suggest the capability of NCL7 composition to induce bioactivity [24].
Furthermore, for this silicate-based glass the nucleation of globular
precipitates was associated with the formation of micro-cracks
(Fig. 4(c)). Crack development is usually a common morphological
feature, part of the dual reaction of formation of a silica-rich film and
growth of calcium-phosphate HCA layer, which is typical of bioactive
materials [1].
Fig. 2. XRD patterns of: a) NCL2, b) NCL4, c) NCL7 and d) AW before sintering (nS) and after sintering (S). • diopside, ♦ silver,▲ hydroxylapatite, and ■ β-wollastonite.
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Fig. 3. On the left, morphological (5Kx mag) and compositional analysis (at%) of NCL2 bioceramic pellet: a) before immersion in SBF, b) after 7 days and c) after 28 days of immersion
in SBF, with the inset showing the precipitate morphology (10Kx). On the right, morphological (5Kx mag) and compositional analysis (at%) of NCL7 bioceramic pellet: d) before
immersion in SBF, e) after 7 days and f) after 28 days of immersion in SBF, with the inset showing the precipitate morphology (10Kx).
Fig. 4. On the left, morphological (5Kx mag) and compositional analysis (at%) of NCL7 bioceramic pellet: a) before immersion in SBF, b) after 7 days and c) after 28 days of immersion
in SBF, with the inset showing the precipitate morphology (10Kx). On the right, morphological (5Kx mag) and compositional analysis (at%) of AW bioceramic pellet: d) before
immersion in SBF, e) after 7 days and f) after 28 days of immersion in SBF, with the inset showing the precipitate morphology (10Kx). The red arrows indicate the micro-cracks
formation on the pellet surface.
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Although the NCL2 and NCL7 formulations have similar SiO2, CaO,
and P2O5 content, the more complex formulation of NCL2 glass, based
on the incorporation of many intermediate oxides, might have reduced
its in vitro bioactivity, and thus may explain the absence of even HA
precursors on its surface [25]. Specifically, the presence of Fe2O3 and
MgO with respect to other bioglasses in SiO2 - CaO - P2O5 system, and
their higher content in comparison to the NCL7 main formulation,
could have affected the morphology of the precipitates and the NCL2
bioactive process [26,27].
Globular and flake shaped agglomerates, rich in calcium and
phosphorous, were identified on the NCL4 borate-based pellet surface,
which increased after 28 days of soaking, as demonstrated by the Ca/P
ratio that moved from 0.76 at day 7 (Fig. 3(d)) to 1.08 at day 28
(Fig. 3(f)) leading to the formation of dicalcium phosphate precipitates
[24]. Globular agglomerates have been previously observed for less
complex borate-based compositions after immersion in SBF [28];
however, for more complex NCL4 composition, the presence of oxides
such as MoO3 and SeO2 might have delayed the formation of the
precipitates.
The extensively documented bioactive properties of AW glass-
ceramic [29] were further proved in this study. After 7 days in
immersion, AW sintered pellets were already completely covered by
an HCA layer, which at day 28 reached a Ca/P ratio (Fig. 4(f)) nearly
equal to the stoichiometric hydroxyapatite (Ca/P=1.67). It is interest-
ing to observe that although the Ca/P ratio of NCL7 precipitates was
lower than AW after 28 days in SBF immersion, conversely the crack
formation process was more pronounced on the NCL7 than the AW-
derived pellets. As suggested by previous studies [1,13,30], this
behaviour is considered the initial stage of the formation of the HCA
layer on glass and glass-ceramic surface, and hence can be considered a
promising feature towards the bioactive potential of NCL7 formulation.
In this study a quantitative elemental characterisation of the sample
surfaces before and after soaking in SBF was assessed by XPS analysis,
in order to estimate the atomic concentration of the main elements (Si,
Ca and P) involved during the bioactivity process [5]. The XPS results
(see Fig. 5) evidenced that the atomic concentration of calcium and
phosphorous on the surface of NCL4, NCL7 and AW sintered pellets
increased already after 24 h in immersion, reaching values higher than
silicon and above 40% after 28 days of soaking. It is interesting to note
that conversely to AW-based samples (Fig. 5(d)), the level of calcium
on the surface of NCL4 and NCL7-based pellets (Fig. 5(b)and (c)) was
lower than phosphorous for the entire time interval. This behaviour
might, therefore, suggest the presence of HA precursor (as indicated by
the EDX analysis), and hence the slower bioactive process for both
NCL4 and NCL7 compositions.
Regarding NCL2-based pellets (see Fig. 5(a)), after immersion in
SBF solution only the calcium level increased, whereas phosphorous
remained almost steady (~9.5 after 28 days in immersion). The lower
diffusion of phosphorous from the outermost surface of NCL2-based
pellets, in comparison to the other formulations, confirmed the lack of
bioactivity of this composition.
Fig. 5. Atomic concentration of Si, Ca and P on the upper surface of a) NCL2, b) NCL4, c) NCL7 and d) AW bioceramic pellets after immersion in SBF solution up to 28 days.
Fig. 6. Averaged weight loss ( ± SD) of NCL2, NCL4, NCL7 and AW pellets after soaking
in SBF solution up to 28 days.
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3.3. pH variation, weight loss and ionic release potential
Usually glass-based structures are known to dissolve in aqueous
solutions with a variable rate depending on the kind of network former
and its percentage in the glass structure [31].
For the fabricated pellets, the in vitro degradation behaviour was
assessed by measuring pellet weight loss after SBF immersion (see
Fig. 6). NCL2 silicate-based structures showed the lowest degradation
rate all over the considered interval. The negligible weight loss of this
class of samples is consistent with the low degradation rate shown by
its diopside crystalline phase upon immersion in physiological fluids
[22]. NCL7 and AW specimens showed a similar trend upon SBF
immersion, reaching a mass loss around 12% and 14% respectively,
after 28 days of soaking.
Considering the NCL4 samples, at the beginning small variations
were observed; then from 3 to 28 days a greater weight loss was
measured. These findings confirmed that borate-based glasses have a
faster dissolution rate [32–35].
On the other hand, the degradation process of a bioactive glass
takes place by ionic exchange of soluble ions, which, depending on the
glass composition, influence the pH of the surrounding media [36]. In
order to evaluate the hydrolytical stability of the bioceramic pellets
after immersion in SBF, the pH changes during the 28 days of
immersion were assessed.
Fig. 7 shows the pH variation as function of the soaking time
resulting from the solubility/ionic exchange reactions at the solid/
liquid interface [37], during the 28 days of immersion in SBF. It can be
observed that all the compositions were characterised by a low pH
variation over the period, which ranged between 7.44 and 7.74.
According to the mechanism proposed by Hench, the pH of the solution
rises very fast initially, followed by marginal change in pH with respect
to time [5]. In the present case, the almost stable pH values might be
governed by the total sum of both basic and acidic ion concentration
present in the main composition [27]. pH values around 7 are usually
considered optimal in provision of future in vitro cell culture [38].
In addition, the ionic leaching potential of the sintered pellets
soaked in SBF solution was assessed by measuring the amount of Si,
Ca, and P released into the media after each time interval. According to
the ICP analysis data (see Fig. 8), the highest release of phosphorous
occurred for AW composition (Fig. 8(d)), which further proved the
bioactivity of this materials [29]. By comparing the silicon leaching
profiles for NCL2, NCL4 and NCL7 sintered pellets (Fig. 8(a)–(c)), it is
interesting to observe that the presence of boron in the glass structure
greatly enhanced the release of this ion. In fact, after 3 days in
immersion the concentration of silicon released from NCL4-based
pellets reached a value more than 3 times higher with respect to the
silicon released from NCL2 and NCL7-based samples. These findings
confirm that borate-based glasses have a highly reactive nature
[31,35,39], and once in solution they can contribute to the dissolution
of the other elements present in the glass network.
Fig. 7. Averaged pH value ( ± SD) of SBF solution for NCL2, NCL4, NCL7 and AW
samples.
Fig. 8. Release profiles of Si, Ca and P ions from a) NCL2, b) NCL4, c) NCL7 and d) AW bioceramic pellets immersed in SBF solution.
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4. Conclusion
Three highly complex glass compositions, NCL2, NCL7 (SiO2-
based) and NCL4 (B2O3-based) were sintered in form of dense pellets,
following the data derived from HSM analysis. The XRD investigation
showed the glass-ceramic nature of NCL2, NCL7 and AW compositions
after sintering, whilst the NCL4 formulation remained completely
amorphous. The sensitivity of the novel materials on apatite forming
ability and biodegradation behaviour was assessed by XRD, SEM, EDS,
XPS, ICP and pH variation during 28 days of immersion in SBF. The
experimental results have indicated that two similar silicate glass
formulations (NCL2 and NCL7) showed markedly different responses
in terms of apatite forming ability, microstructure of the precipitates,
and dissolution in SBF. The less complex of the two glass formulations,
NCL7, exhibited the greatest bioactive potential, while NCL2 showed
no apatite precipitates after 28 days in SBF immersion. Furthermore,
NCL4 displayed the highest degradation rate, confirming the highly
reactive nature of borate-based glass compositions.
In conclusion, the complexity of glass formulations affects signifi-
cantly in vitro bioactivity and degradation behaviour of these materials,
as very small variations in glass formulations, (even less than 2 wt%),
can change completely their bioactivity and solubility. The combined
effect of ions released in aqueous solutions (such as SBF) can enhance
or inhibit dissolution and precipitation rates of these materials.
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